U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Early Unfavorable Non-Hodgkin Lymphoma

MedGen UID:
313146
•Concept ID:
C1707876
•
Neoplastic Process
Synonym: Early Unfavorable Non-Hodgkin's Lymphoma

Definition

A clinical stage I or II non-Hodgkin lymphoma with at least one of the following risk factors: large mediastinal mass, extranodal spread, elevated erythrocyte sedimentation rate, involvement of at least three lymph node areas, and B symptoms. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVEarly Unfavorable Non-Hodgkin Lymphoma

Professional guidelines

PubMed

Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M, Huntington SF, Olszewski AJ
Oncologist 2021 Feb;26(2):120-132. Epub 2020 Dec 9 doi: 10.1002/onco.13610. PMID: 33230948Free PMC Article
Management of Early-stage Hodgkin Lymphoma: A Practice Guideline.
Herst J, Crump M, Baldassarre FG, MacEachern J, Sussman J, Hodgson D, Cheung MC
Clin Oncol (R Coll Radiol) 2017 Jan;29(1):e5-e12. Epub 2016 Sep 30 doi: 10.1016/j.clon.2016.09.006. PMID: 27697411
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS; Expert Panel on Radiation OncologyLymphoma
Am J Clin Oncol 2016 Aug;39(4):384-95. doi: 10.1097/COC.0000000000000294. PMID: 27299425

Recent clinical studies

Etiology

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B
J Clin Oncol 2023 Feb 20;41(6):1193-1199. Epub 2022 Dec 12 doi: 10.1200/JCO.22.02355. PMID: 36508302
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A
Lancet Oncol 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. PMID: 33539742
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M, Huntington SF, Olszewski AJ
Oncologist 2021 Feb;26(2):120-132. Epub 2020 Dec 9 doi: 10.1002/onco.13610. PMID: 33230948Free PMC Article
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group
Lancet 2015 May 9;385(9980):1853-62. Epub 2015 Mar 19 doi: 10.1016/S0140-6736(15)60165-9. PMID: 25796459
Relapse in Burkitt's lymphoma.
Nkrumah FK, Perkins IV
Int J Cancer 1976 Apr 15;17(4):455-60. doi: 10.1002/ijc.2910170407. PMID: 1279038

Diagnosis

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A
Lancet Oncol 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. PMID: 33539742
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M, Huntington SF, Olszewski AJ
Oncologist 2021 Feb;26(2):120-132. Epub 2020 Dec 9 doi: 10.1002/onco.13610. PMID: 33230948Free PMC Article
The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.
Kim Y, Kim SJ, Hwang D, Jang J, Hyun SY, Kim YR, Kim JS, Min YH, Cheong JW
Yonsei Med J 2014 Nov;55(6):1568-75. doi: 10.3349/ymj.2014.55.6.1568. PMID: 25323893Free PMC Article
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291
Hodgkin's disease: management of first relapse.
Yuen AR, Horning SJ
Oncology (Williston Park) 1996 Feb;10(2):233-40, 245; discussion 245-6, 249-. PMID: 8838268

Therapy

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup
J Clin Oncol 2023 Jan 10;41(2):327-335. Epub 2022 Jul 22 doi: 10.1200/JCO.21.01281. PMID: 35867960
Mexican consensus on Hodgkin's lymphoma.
Álvarez-Vera JL, Aguilar-Luevano J, Alcívar-Cedeño LM, Arana-Luna LL, Arteaga-Ortiz L, Báez-Islas PE, Carolina-Reynoso A, Cesarman-Maus G, Peña-Celaya JA, Espitia-Ríos ME, Fermín-Caminero DJ, Flores-Patricio W, García-Camacho AS, Guzmán-Mora PG, Hernández-Colín AK, Hernández-Ruiz E, Herrera-Olivares W, Jacobo-Medrano E, Loera-Fragoso SJ, Macías-Flores JP, Martínez-Ramírez MA, Medina-Guzmán L, Milán-Salvatierra AI, Montoya-Jiménez L, Morales-Adrián JJ, Mujica-Martínez A, Nava-Villegas L, Orellana-Garibay JJ, Palma-Moreno OG, Pérez-Zúñiga JM, Pérez-Gómez KD, Pichardo-Cepín YM, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Segura-García A, Silva-Vera K, Tapía-Enríquez AL, Teomitzi-Sánchez Ó, Tepepa-Flores F, Vilchis-González SP, Villela-Peña A, Guerra-Alarcón LV, Reséndiz-Olea R, Banda-García L, Paredes-Lozano EP, Alvarado-Ibarra M
Gac Med Mex 2021;157(Suppl 2):S1-S16. doi: 10.24875/GMM.M21000534. PMID: 34324483
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M, Huntington SF, Olszewski AJ
Oncologist 2021 Feb;26(2):120-132. Epub 2020 Dec 9 doi: 10.1002/onco.13610. PMID: 33230948Free PMC Article
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group
Lancet 2015 May 9;385(9980):1853-62. Epub 2015 Mar 19 doi: 10.1016/S0140-6736(15)60165-9. PMID: 25796459
Relapse in Burkitt's lymphoma.
Nkrumah FK, Perkins IV
Int J Cancer 1976 Apr 15;17(4):455-60. doi: 10.1002/ijc.2910170407. PMID: 1279038

Prognosis

Early Organ Metastasis in Granulomatous Mycosis Fungoides: A Systematic Review.
Motamedi M, Xiao MZX, Deschenes J, Hardin J, Sterrett R, Street L, Taparia M, Mahe E, Ferrara G, Barrie JR, Gniadecki R
Dermatology 2024;240(3):468-473. Epub 2024 Feb 29 doi: 10.1159/000537893. PMID: 38422999
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup
J Clin Oncol 2023 Jan 10;41(2):327-335. Epub 2022 Jul 22 doi: 10.1200/JCO.21.01281. PMID: 35867960
Mexican consensus on Hodgkin's lymphoma.
Álvarez-Vera JL, Aguilar-Luevano J, Alcívar-Cedeño LM, Arana-Luna LL, Arteaga-Ortiz L, Báez-Islas PE, Carolina-Reynoso A, Cesarman-Maus G, Peña-Celaya JA, Espitia-Ríos ME, Fermín-Caminero DJ, Flores-Patricio W, García-Camacho AS, Guzmán-Mora PG, Hernández-Colín AK, Hernández-Ruiz E, Herrera-Olivares W, Jacobo-Medrano E, Loera-Fragoso SJ, Macías-Flores JP, Martínez-Ramírez MA, Medina-Guzmán L, Milán-Salvatierra AI, Montoya-Jiménez L, Morales-Adrián JJ, Mujica-Martínez A, Nava-Villegas L, Orellana-Garibay JJ, Palma-Moreno OG, Pérez-Zúñiga JM, Pérez-Gómez KD, Pichardo-Cepín YM, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Segura-García A, Silva-Vera K, Tapía-Enríquez AL, Teomitzi-Sánchez Ó, Tepepa-Flores F, Vilchis-González SP, Villela-Peña A, Guerra-Alarcón LV, Reséndiz-Olea R, Banda-García L, Paredes-Lozano EP, Alvarado-Ibarra M
Gac Med Mex 2021;157(Suppl 2):S1-S16. doi: 10.24875/GMM.M21000534. PMID: 34324483
Hodgkin's disease: management of first relapse.
Yuen AR, Horning SJ
Oncology (Williston Park) 1996 Feb;10(2):233-40, 245; discussion 245-6, 249-. PMID: 8838268
Relapse in Burkitt's lymphoma.
Nkrumah FK, Perkins IV
Int J Cancer 1976 Apr 15;17(4):455-60. doi: 10.1002/ijc.2910170407. PMID: 1279038

Clinical prediction guides

Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F, Liu H, Meng X, Liu J, Wang J, Yu J, Liu X, Liu X, Li L, Qiu L, Qian Z, Zhou S, Gong W, Meng B, Ren X, Golchehre Z, Chavoshzadeh Z, He J, Zhang H, Wang X
Br J Haematol 2023 Sep;202(6):1151-1164. Epub 2023 Jul 16 doi: 10.1111/bjh.18974. PMID: 37455019
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B
J Clin Oncol 2023 Feb 20;41(6):1193-1199. Epub 2022 Dec 12 doi: 10.1200/JCO.22.02355. PMID: 36508302
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup
J Clin Oncol 2023 Jan 10;41(2):327-335. Epub 2022 Jul 22 doi: 10.1200/JCO.21.01281. PMID: 35867960
The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.
Kim Y, Kim SJ, Hwang D, Jang J, Hyun SY, Kim YR, Kim JS, Min YH, Cheong JW
Yonsei Med J 2014 Nov;55(6):1568-75. doi: 10.3349/ymj.2014.55.6.1568. PMID: 25323893Free PMC Article
Relapse in Burkitt's lymphoma.
Nkrumah FK, Perkins IV
Int J Cancer 1976 Apr 15;17(4):455-60. doi: 10.1002/ijc.2910170407. PMID: 1279038

Recent systematic reviews

Early Organ Metastasis in Granulomatous Mycosis Fungoides: A Systematic Review.
Motamedi M, Xiao MZX, Deschenes J, Hardin J, Sterrett R, Street L, Taparia M, Mahe E, Ferrara G, Barrie JR, Gniadecki R
Dermatology 2024;240(3):468-473. Epub 2024 Feb 29 doi: 10.1159/000537893. PMID: 38422999
Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
Xie M, Jiang Q, Zhao S, Zhao J, Ye X, Qian W
Int Immunopharmacol 2020 Aug;85:106684. Epub 2020 Jun 12 doi: 10.1016/j.intimp.2020.106684. PMID: 32540726
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N
Cochrane Database Syst Rev 2015 Jan 9;1(1):CD010533. doi: 10.1002/14651858.CD010533.pub2. PMID: 25572491Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...